With Venture Cash, Pronutria Mines Food Supply For Drugs And Supplements
This article was originally published in Start Up
Amino acids and protein mixtures are nothing new to bodybuilders and people whose diseases require special diets. The new Flagship company wants to make better cocktails, backed by clinical data.
You may also be interested in...
Agency makes clear that triglyceride levels are no longer an acceptable surrogate for reducing cardiovascular risk.
AstraZeneca agreed to pay $260 million plus contingency payments to acquire Omthera, the makers of the omega-3 product Epanova, which is ready for regulatory filing for dyslipidemia. The deal raises questions for Amarin, whose similar product Vascepa has reached the market without a big pharma partner.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.